The most profound inhibition was, however, noticed in the case of applications of the combination of mTOR inhibitor—everolimus, with PI3K kinase inhibitor—LY294002, which reduced proliferation of Lu1205 metastatic melanoma cells by 62% (p < 0.0005) in (Fig. 1b). Here, MTOR is linked to metastatic melanoma.